Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GE HealthCare Technologies Inc.GEHC · Entity 1711 | CEO, Imaging | May 13, 2024 | May 15, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GE HealthCare Technologies Inc.
Report date May 13, 2024 · Filed May 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 63,348 |
Ending reported balance
After 2024-05-15 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2024-05-13 · Exercise / conversion · Acquired 20,227 · Balance 83,575 Row 2 · 2024-05-13 · Sale · Disposed 20,227 · Balance 63,348 F1: The price reported represents the weighted average price of shares sold. These shares were sold in multiple transactions at prices ranging from $81.50 to $81.84, inclusive. The Reporting Person undertakes to provide GE HealthCare Technologies Inc. ("GE HealthCare"), any security holder of GE HealthCare, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). Row 3 · 2024-05-15 · Exercise / conversion · Acquired 8,388 · Balance 71,736 Row 4 · 2024-05-15 · Exercise / conversion · Acquired 25,472 · Balance 97,208 Row 5 · 2024-05-15 · Exercise / conversion · Acquired 33,095 · Balance 130,303 Row 6 · 2024-05-15 · Sale · Disposed 66,955 · Balance 63,348 F2: The price reported represents the weighted average price of shares sold. These shares were sold in multiple transactions at prices ranging from $81.50 to $81.68, inclusive. The Reporting Person undertakes to provide GE HealthCare, any security holder of GE HealthCare, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.51 · Expires 2030-03-02 | Direct | 8,388 |
Reported balance
After 2024-05-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-05-13 · Exercise / conversion · Disposed 20,227 · Balance 8,388 F3: Award of an employee stock option with respect to GE HealthCare common stock resulting from the conversion of certain equity incentive awards previously granted by General Electric Company ("GE") as a result of the consummation on January 3, 2023 of the distribution of approximately 80.1% of the shares of common stock of GE HealthCare by GE to holders of GE common stock on a pro rata basis (the "Spin-Off"), of which 100% became exercisable on March 2, 2023. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.51 · Expires 2030-03-02 | Direct | 0 |
Reported balance
After 2024-05-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-05-15 · Exercise / conversion · Disposed 8,388 · Balance 0 F3: Award of an employee stock option with respect to GE HealthCare common stock resulting from the conversion of certain equity incentive awards previously granted by General Electric Company ("GE") as a result of the consummation on January 3, 2023 of the distribution of approximately 80.1% of the shares of common stock of GE HealthCare by GE to holders of GE common stock on a pro rata basis (the "Spin-Off"), of which 100% became exercisable on March 2, 2023. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.30 · Expires 2033-03-01 | Direct | 0 |
Reported balance
After 2024-05-15 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-05-15 · Exercise / conversion · Disposed 25,472 · Balance 0 F4: Award of an employee stock option with respect to GE HealthCare common stock, of which 100% became exercisable on March 1, 2024. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.37 · Expires 2031-07-01 | Direct | 33,096 |
Reported balance
After 2024-05-15 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-05-15 · Exercise / conversion · Disposed 33,095 · Balance 33,096 F5: Award of an employee stock option with respect to GE HealthCare common stock resulting from the conversion of certain equity incentive awards previously granted by GE as a result of the Spin-Off, of which 50% became exercisable on July 1, 2023 and 50% will become exercisable on July 1, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported represents the weighted average price of shares sold. These shares were sold in multiple transactions at prices ranging from $81.50 to $81.84, inclusive. The Reporting Person undertakes to provide GE HealthCare Technologies Inc. ("GE HealthCare"), any security holder of GE HealthCare, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).
F2: The price reported represents the weighted average price of shares sold. These shares were sold in multiple transactions at prices ranging from $81.50 to $81.68, inclusive. The Reporting Person undertakes to provide GE HealthCare, any security holder of GE HealthCare, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).
F3: Award of an employee stock option with respect to GE HealthCare common stock resulting from the conversion of certain equity incentive awards previously granted by General Electric Company ("GE") as a result of the consummation on January 3, 2023 of the distribution of approximately 80.1% of the shares of common stock of GE HealthCare by GE to holders of GE common stock on a pro rata basis (the "Spin-Off"), of which 100% became exercisable on March 2, 2023.
F4: Award of an employee stock option with respect to GE HealthCare common stock, of which 100% became exercisable on March 1, 2024.
F5: Award of an employee stock option with respect to GE HealthCare common stock resulting from the conversion of certain equity incentive awards previously granted by GE as a result of the Spin-Off, of which 50% became exercisable on July 1, 2023 and 50% will become exercisable on July 1, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2023 Filed Jan 6, 2023 01:47 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | GrantEmployee Stock Option (right to buy) · Derivative | 1,469 | Not disclosed Strike: $129.52 | Not disclosed |
DisclosureSEC source: 0000899243-23-001113 · doc4.xml · derivative · entry 2 Makela Jan · CIK 0001951803 · CEO, Imaging 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,469 Underlying: Common stock, par value $0.01 per share · 1,469 shares Expires 2023-09-13 F1 · price: The transactions reported herein are the result of the consummation on January 3, 2023 of the distribution of approximately 80.1% of the shares of common stock of GE HealthCare Technologies Inc. ("GE HealthCare") by General Electric Company ("GE") to holders of GE common stock on a pro rata basis (the "Spin-Off"). These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9. F2 · derivative.exercise_date: Award of an employee stock option with respect to GE HealthCare common stock resulting from the conversion of certain equity incentive awards previously granted by GE as a result of the Spin-Off, of which 100% is fully exercisable immediately. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 01:47 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | GrantCommon stock, par value $0.01 per share | 32 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-001113 · doc4.xml · nonDerivative · entry 1 Makela Jan · CIK 0001951803 · CEO, Imaging 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32 F1 · shares: The transactions reported herein are the result of the consummation on January 3, 2023 of the distribution of approximately 80.1% of the shares of common stock of GE HealthCare Technologies Inc. ("GE HealthCare") by General Electric Company ("GE") to holders of GE common stock on a pro rata basis (the "Spin-Off"). These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9. F1 · price: The transactions reported herein are the result of the consummation on January 3, 2023 of the distribution of approximately 80.1% of the shares of common stock of GE HealthCare Technologies Inc. ("GE HealthCare") by General Electric Company ("GE") to holders of GE common stock on a pro rata basis (the "Spin-Off"). These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.